Drug Discovery World

FEBRUARY 8, 2024

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers. Why are those important?

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

Drug Discovery World

OCTOBER 3, 2023

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

Drug Discovery World

MAY 16, 2023

New South African company NewBiologix has launched with the aim of developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. Current gene and cell therapies primarily focus on rare diseases.

Production 52

Production Gene Therapy Gene Bioinformatics 52

Drug Discovery World

OCTOBER 20, 2023

GenomeFrontier partners with BioCina on CAR-T therapy CDMO BioCina and GenomeFrontier Therapeutics will partner on the development of virus-free CAR-T products for cancer treatment. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

Drug Discovery World

APRIL 29, 2024

Jean-Baptiste Agnus, Chief Business Officer, and Peter Carbone, Chief Quality Officer, KBI Biopharma: Agnus brings more than two decades of experience in the biopharmaceutical industry with expertise in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and cell and gene therapies.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Marine Houdou, Genetic Engineering Specialist, Polyplus, on: ‘From modular DNA assembly to recombinant protein production at Polyplus’. The session ends with two presentations and two luncheon presentations.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion.

Protein 59

Protein Antibody Engineer Scientist 59